Morgan Stanley’s Sonnet BioTherapeutics SONN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-25,808
| Closed | -$118K | – | 8435 |
|
|
2025
Q3 | $118K | Buy |
+25,808
| New | +$114K | ﹤0.01% | 6078 |
|
|
2024
Q3 | – | Sell |
-1
| Closed | -$4 | – | 8017 |
|
|
2024
Q2 | $4 | Hold |
1
| – | – | ﹤0.01% | 7813 |
|
|
2024
Q1 | $11 | Sell |
1
-14
| -93% | -$188 | ﹤0.01% | 7762 |
|
|
2023
Q4 | $212 | Sell |
15
-3
| -17% | -$41 | ﹤0.01% | 7341 |
|
|
2023
Q3 | $407 | Hold |
18
| – | – | ﹤0.01% | 7328 |
|
|
2023
Q2 | $1.54K | Buy |
18
+12
| +200% | +$846 | ﹤0.01% | 7233 |
|
|
2023
Q1 | $411 | Hold |
6
| – | – | ﹤0.01% | 7454 |
|
|
2022
Q4 | $1.31K | Buy |
6
+5
| +500% | +$1.09K | ﹤0.01% | 7433 |
|
|
2022
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 7859 |
|
|
2022
Q2 | $1K | Hold |
1
| – | – | ﹤0.01% | 7703 |
|
|
2022
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 8103 |
|
|
2021
Q4 | $1K | Hold |
1
| – | – | ﹤0.01% | 7884 |
|
|
2021
Q3 | $1K | Hold |
1
| – | – | ﹤0.01% | 7799 |
|
|
2021
Q2 | $2K | Hold |
1
| – | – | ﹤0.01% | 7538 |
|
|
2021
Q1 | $3K | Hold |
1
| – | – | ﹤0.01% | 7220 |
|
|
2020
Q4 | $3K | Buy |
+1
| New | +$6.36K | ﹤0.01% | 6853 |
|
|
2017
Q3 | – | Hold |
0
| – | -$2K | – | 6605 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6465 |
|
|
2016
Q2 | – | Hold |
0
| – | -$1K | – | 6646 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6483 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 5475 |
|
|
2015
Q3 | – | Hold |
0
| – | -$3K | – | 6713 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6478 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 6373 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6659 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 6656 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 6596 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 6539 |
|
Other funds holding SONN
Morgan Stanley's SONN Position: Q4 2025 in Review
Morgan Stanley sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 25,808 shares — an estimated $118K sold.
Morgan Stanley first reported a position in SONN in Q4 2020 and held it in 16 quarters. The position peaked at $118K in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.
- Morgan Stanley reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
- Morgan Stanley sold 25,808 Sonnet BioTherapeutics shares in Q4 2025, an estimated $118K.
- Morgan Stanley first reported a position in Sonnet BioTherapeutics in Q4 2020 and held it in 16 quarters.
- Morgan Stanley's Sonnet BioTherapeutics position peaked at $118K in Q3 2025.
- 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.
Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.